Potential investors in Anthropic have lowered the companys valuation from $2 trillion to $1.2–1.3 trillion, while rival AI lab OpenAI raised funds in a round valued at $1.25 trillion / Photo: miss.cabul / Shutterstock.com
News·
OpenAI Catches Up to Anthropic, Deals a Blow to Rival Nebius: Key Takeaways on the IPO Ahead of November 8
The more news there is surrounding specific stories, the more strongly investors react to them, and the more a companys stock price falls. Photo: Unsplash / AbsolutVision
Review·
Getting Stuck on the Same Thing: How News Concentration Affects Investors' Decisions
Leading Wall Street strategists see the recent selloff as a buying opportunity and are sticking to bullish year-end targets for the S&P 500 / Photo: Shutterstock.com
News·
'Air is coming out of the AI bubble': Strategists urge investors to buy after rout
Berkshires executives are actively buying back shares, believing them to be undervalued, but Wall Street disagrees / Photo: frank333 / Shutterstock.com
News·
Berkshire has sharply accelerated its share buybacks. Should investors buy these shares?
Small Caps·
Small caps last week: Inovio approval, Alstom guidance cut, Once Upon a Farm recall
Review·
A Blow to Elon Musk, “Guppy Fry” in the Ocean of AI, Kazakhstan’s Radioactive Armor
Review·
The Race Between Caesars and Fanatics: What the New Book on the Future of AI Has to Say
News·
Burry cut his position in an AI-boom beneficiary by 75%. What other trades did he disclose?
Stock Screener
Buy
Sell
Go to section
Guru Portfolios

Track the investments of top funds and market legends

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Go to section
Small Caps
Innodata shares are off 30% year to date, while all four analysts tracked by MarketWatch have it at buy / Photo: Shutterstock.com
Small Caps·
Innodata reports 3Q earnings, raises outlook; eyes growth in AI agents and robots
Small Caps·
Defense tech Lyntris soars on earnings. One analyst sees another 120% upside.
Small Caps·
Where to invest $1,000 amid the AI selloff: Snacks, med tech, and real estate
Small Caps·
Nurix plunges 38% after Sanofi scraps drug licensed from the biotech
Small Caps·
Crafting platform Cricut hits three-year high as 3Q earnings crush expectations
Go to section

Investment and Finance News